Pemetrexed Disodium and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01001910|
Recruitment Status : Completed
First Posted : October 27, 2009
Last Update Posted : December 14, 2015
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma||Drug: Carboplatin Other: Laboratory Biomarker Analysis Drug: Pemetrexed Disodium||Phase 2|
I. To evaluate the response rate of combination pemetrexed (pemetrexed disodium) (Alimta) and carboplatin (Paraplatin) in recurrent ovarian, primary peritoneal, and fallopian tube carcinoma.
I. To evaluate the progression free interval, overall survival, and adverse effects among patients receiving this drug combination.
Patients receive pemetrexed disodium intravenously (IV) over 8-15 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma|
|Study Start Date :||July 2008|
|Actual Primary Completion Date :||January 2015|
|Actual Study Completion Date :||February 2015|
Experimental: Treatment (pemetrexed disodium, carboplatin)
Patients receive pemetrexed disodium IV over 8-15 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
Other: Laboratory Biomarker Analysis
Drug: Pemetrexed Disodium
- Overall objective response rate (RR) based on Response Evaluation Criteria in Solid Tumors and by Rustin Criteria (RECIST) [ Time Frame: Up to 8 years ]An exact 95% confidence interval for the tumor RR will be calculated based on the binomial distribution.
- Incidence of toxicities assessed according to National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 3.0. [ Time Frame: Up to 8 years ]Each of the grade 3 or 4 hematologic and non-hematologic toxicities will be determined and divided by the total number of patients to calculate the frequency for each toxicity over the study population. The number of adverse events will also be divided by the number of chemotherapy cycles to determine the frequency per treatment course.
- Overall survival [ Time Frame: First day of treatment on protocol to the date of death, or for living patients the last date of contact, assessed up to 8 years ]Kaplan-Meier method will be used to analyze the time-to-event data including overall survival.
- Progression-free interval [ Time Frame: Time from the first day of treatment to the day that progression is first noted, assessed up to 8 years ]Kaplan-Meier method will be used to analyze the time-to-event data including progression free interval.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01001910
|United States, New York|
|Albert Einstein College of Medicine|
|Bronx, New York, United States, 10461|
|Columbia University Medical Center|
|New York, New York, United States, 10032|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Dennis Kuo||Albert Einstein College of Medicine|